Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOUND: Fasudil for Dementia Wandering
NCT04793659Phase 2Completed
- Sponsor
- Woolsey Pharmaceuticals, Inc.
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of bravyl in Dementia (3 arms), sponsored by Woolsey Pharmaceuticals, Inc. Primary endpoint: Global Impression of Wandering. Started Dec 2020; status: completed.
02
Drugs
bravyl
03
Conditions
Dementia
Beyond the preview
Go deeper on NCT04793659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04793659.